首页 | 本学科首页   官方微博 | 高级检索  
文章检索
  按 检索   检索词:      
出版年份:   被引次数:   他引次数: 提示:输入*表示无穷大
  收费全文   17880篇
  免费   2071篇
  国内免费   1084篇
耳鼻咽喉   139篇
儿科学   400篇
妇产科学   303篇
基础医学   4084篇
口腔科学   429篇
临床医学   1522篇
内科学   3435篇
皮肤病学   396篇
神经病学   956篇
特种医学   400篇
外国民族医学   12篇
外科学   1426篇
综合类   2745篇
现状与发展   5篇
预防医学   835篇
眼科学   256篇
药学   1393篇
  2篇
中国医学   179篇
肿瘤学   2118篇
  2024年   23篇
  2023年   421篇
  2022年   539篇
  2021年   1139篇
  2020年   848篇
  2019年   815篇
  2018年   693篇
  2017年   642篇
  2016年   673篇
  2015年   832篇
  2014年   1106篇
  2013年   1109篇
  2012年   1137篇
  2011年   1305篇
  2010年   1101篇
  2009年   1129篇
  2008年   1078篇
  2007年   1011篇
  2006年   875篇
  2005年   707篇
  2004年   505篇
  2003年   383篇
  2002年   289篇
  2001年   309篇
  2000年   260篇
  1999年   231篇
  1998年   198篇
  1997年   169篇
  1996年   129篇
  1995年   147篇
  1994年   151篇
  1993年   125篇
  1992年   109篇
  1991年   69篇
  1990年   71篇
  1989年   67篇
  1988年   67篇
  1987年   47篇
  1986年   44篇
  1985年   77篇
  1984年   54篇
  1983年   44篇
  1982年   36篇
  1981年   47篇
  1980年   54篇
  1979年   28篇
  1978年   35篇
  1977年   19篇
  1976年   29篇
  1975年   15篇
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
51.
52.
目的:探讨长链非编码RNA CBR3-AS1(lncRNA CBR3-AS1)在胆管癌(CCA)中表达状态及其临床意义。方法:用qRT-PCR检测lncRNA CBR3-AS1在CCA组织与癌旁组织以及CCA细胞与正常胆管上皮细胞中的表达,分析lncRNA CBR3-AS1表达与CCA患者临床病理参数及生存率的关系。将胆管癌细胞分别转染lncRNA CBR3-AS1过表达质粒(过表达组)、阴性对照质粒(对照组)及lncRNA CBR3-AS1沉默序列(沉默组),用MTT实验与Transwell实验检测各组细胞的增殖与侵袭能力。结果:lncRNA CBR3-AS1的表达在胆管癌组织中明显高于癌旁组织,在胆管癌细胞系中明显高于正常胆管上皮细胞(均P0.01)。lncRNA CBR3-AS1表达与CCA患者淋巴结转移、TNM分期和术后复发明显有关(P0.05)。lncRNA CBR3-AS1高表达患者总生存率明显低于lncRNA CBR3-AS1低表达患者(P=0.004)。lncRNA CBR3-AS1表达(P=0.020)与TNM分期(P=0.014)是影响CCA患者总生存率的独立危险因素。与对照组CCA细胞比较,过表达组CCA细胞增殖与侵袭能力明显增高,沉默组CCA细胞增殖与侵袭能力明显降低(均P0.05)。结论:lncRNA CBR3-AS1在胆管癌中表达升高,升高的lncRNA CBR3-AS1与CCA的恶性临床病理特征及患者的不良预后密切相关。  相似文献   
53.
GBM (glioblastoma multiforme) is the most malignant form of glioma and is the most commonly occurring primary malignant brain tumour. GBM is difficult to completely excise, resulting in an extremely high recurrence rate. The occurrence of an aggressive glioma phenotype depends on EMT (epithelial-mesenchymal transformation), in which epithelial cells transform into mesenchymal cells by losing their cell-cell adhesion and polarity. NcRNAs (non-coding RNAs) play a significant role in the cellular progression from a normal phenotype to a cancerous phenotype. Recently, many studies have shown that there are two essential regulatory ncRNAs, miRNAs (microRNAs) and lncRNAs, which are closely related to EMT. In this review, we conducted a comprehensive investigation of the dysregulated lncRNAs and miRNAs in gliomas with particular attention to the function and regulatory mechanisms of several important lncRNAs and miRNAs, and we discussed their roles as glioma diagnostic and prognostic biomarkers and their potential clinical applications as therapeutic targets.  相似文献   
54.
55.
Introduction: It is now clear that circulating cell-free ribonucleic acids (ccfRNAs), including messenger RNA (mRNA) and miRNA, are potential cancer biomarkers. As ccfmiRNA is relatively more stable than ccfmRNA, research should concentrate on developing novel methods to preserve the stability of ccfmRNA and standardization of the protocol which includes extraction, detection, and multicenter validation.

Areas covered: This literature review concentrates on the potential of ccfRNA being used as a biomarker in cancer, with special focus on mRNAs and microRNAs (miRNAs).

Expert opinion: With the advancement of high-throughput technologies such as RNA sequencing, a panel of biomarkers will be used for the diagnosis, prognosis and therapeutic monitoring of cancer patients. In order to achieve this important target, bioinformatics education to pathologists, scientists, and technologists in molecular diagnostic laboratories is essential. Moreover, the panel of these new ccfRNAs biomarkers has to obtain approval or clearance from an authority such as the US Food and Drug Administration (FDA), and the standard of utilizing these new protocols has to be recognized via accreditation exercise. Therefore, there is still a long way to go before an extensively use of ccfRNA biomarkers in cancer patients can be realized.  相似文献   

56.
57.
目的:探究环状RNA(circRNA)hsa_circ_0001785在乳腺癌组织和细胞中的表达变化及其对乳腺癌细胞增殖、迁移和侵袭能力的影响。方法:qRT-PCR实验检测hsa_circ_0001785在乳腺癌组织和乳腺癌细胞(MDA-MB-231和SK-BP-3)中的相对表达水平;CCK-8和克隆形成实验检测沉默或上调表达hsa_circ_0001785对MDA-MB-231细胞活性和克隆形成能力的影响;划痕愈合实验和Transwell侵袭实验检测沉默或上调表达hsa_circ_0001785对MDA-MB-231细胞迁移及侵袭能力的影响。结果:hsa_circ_0001785在乳腺癌组织中的相对表达水平明显高于癌旁组织,hsa_circ_0001785在MDA-MB-231和SK-BP-3细胞中的相对表达水平明显高于人乳腺上皮细胞MCF10A。在MDA-MB-231细胞沉默hsa_circ_0001785,MDA-MB-231细胞的活性和克隆形成能力明显降低,迁移距离显著减少,侵袭能力也明显下降。而在MDA-MB-231细胞中上调表达hsa_circ_0001785,MDA-MB-231细胞的活性和克隆形成能力显著升高,迁移距离明显升高,侵袭能力也明显升高。结论:hsa_circ_0001785在乳腺癌组织和乳腺癌细胞(MDA-MB-231和SK-BP-3)中的表达水平明显升高;沉默hsa_circ_0001785显著抑制乳腺癌MDA-MB-231细胞的增殖、迁移和侵袭能力,而上调表达hsa_circ_0001785明显促进乳腺癌MDA-MB-231细胞的增殖、迁移和侵袭能力。  相似文献   
58.

Background

Although serial transverse enteroplasty (STEP) improves function of dilated short bowel, a significant proportion of patients require repeat surgery. To address underlying reasons for unsuccessful STEP, we compared small intestinal mucosal characteristics between initial and repeat STEP procedures in children with short bowel syndrome (SBS).

Methods

Fifteen SBS children, who underwent 13 first and 7 repeat STEP procedures with full thickness small bowel samples at median age 1.5 years (IQR 0.7–3.7) were included. The specimens were analyzed histologically for mucosal morphology, inflammation and muscular thickness. Mucosal proliferation and apoptosis was analyzed with MIB1 and Tunel immunohistochemistry.

Results

Median small bowel length increased 42% by initial STEP and 13% by repeat STEP (p = 0.05), while enteral caloric intake increased from 6% to 36% (p = 0.07) during 14 (12-42) months between the procedures. Abnormal mucosal inflammation was frequently observed both at initial (69%) and additional STEP (86%, p = 0.52) surgery. Villus height, crypt depth, enterocyte proliferation and apoptosis as well as muscular thickness were comparable at first and repeat STEP (p > 0.05 for all). Patients, who required repeat STEP tended to be younger (p = 0.057) with less apoptotic crypt cells (p = 0.031) at first STEP. Absence of ileocecal valve associated with increased intraepithelial leukocyte count and reduced crypt cell proliferation index (p < 0.05 for both).

Conclusions

No adaptive mucosal hyperplasia or muscular alterations occurred between first and repeat STEP. Persistent inflammation and lacking mucosal growth may contribute to continuing bowel dysfunction in SBS children, who require repeat STEP procedure, especially after removal of the ileocecal valve.

Level of evidence

Level IV, retrospective study.  相似文献   
59.
目的 探讨前列腺癌非编码RNA1(PRNCR1)在前列腺癌早期诊断及预后的价值。方法 选取2012年1月至2015年10月在本院诊治前列腺癌患者45例、良性前列腺增生患者88例,进行PRNCR1检验。结果 PRNCR1 检验的灵敏度84.4%(38/45)、特异度90.9%(80/88)、阳性预测值82.6%(38/46)、阴性预测值92.0%(80/87)、符合率88.7%(118/133),PRNCR1在前列腺癌组织中含量高于癌旁组织和良性前列腺增生组织,差异有统计学意义(P<0.05)。两年内转移、复发、肿瘤死亡患者30例,其PRNCRA表达量高于两年内无转移、复发、死亡的患者(15例),差异有统计学意义(P<0.05)。结论 PRNCR1表达在诊断前列腺癌有价值,PRNCR1高表达与患者预后不良有关。  相似文献   
60.

Background

We report the first-in-concept human trial of the safety, tolerability and immunogenicity when a novel TLR 7/8/RIG I agonist RNA-based adjuvant, CV8102, was administered alone or mixed with fractional doses of a licensed rabies vaccine (Rabipur®) as model antigen.

Methods

The primary objective was to assess the safety and reactogenicity of various dose levels of CV8102 alone or mixed with Rabipur® in healthy 18–40 year-old male volunteers. A secondary objective was to assess the immune-enhancing potential of bedside-mixes of CV8102 with fractional doses of Rabipur® by measuring induction of rabies virus neutralising titres (VNTs).

Results

Fifty-six volunteers received 50–100?μg CV8102 alone (n?=?11), bedside-mixed CV8102 and Rabipur® (n?=?20), or Rabipur® alone (n?=?25; control). When given alone or mixed with Rabipur® CV8102 caused mostly Grade 1 or 2 local or systemic reactogenicity, but no related SAEs. As 100?µg CV8102 was associated with marked CRP increases further dose escalation was stopped. Combining 25–50?µg of CV8102 with fractional doses of Rabipur® significantly improved the kinetics of VNT responses; 50?µg CV8102 also improved the magnitude of VNT responses to 1/10 Rabipur® but caused severe but self-limiting influenza-like symptoms in 2 of 14 subjects.

Conclusions

Doses of 25 and 50?µg CV8102 appeared safe and with an acceptable reactogenicity profile while significantly enhancing the immunogenicity of fractional doses of rabies vaccine.EudraCT No. 2013-004514-18.  相似文献   
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号